Are statins right for a 69 year old male

The short version: for a 69-year-old man without a prior heart attack or stroke, the evidence for statins is thin and the benefit is small. For a man who has already had a heart attack or stroke, the evidence is stronger but still comes with real trade-offs.

The answer depends entirely on whether this is primary prevention (no prior cardiovascular event) or secondary prevention (already had a heart attack, stroke, or revascularization). The evidence for the two situations is not the same.

For secondary prevention in older adults, the PROSPER trial tested pravastatin 40 mg in people aged 70-82 with known vascular disease. It found a 22% relative reduction in the combined endpoint of coronary death, non-fatal heart attack, or stroke (hazard ratio 0.78, 95% CI 0.66-0.93) [13]. That is a real effect. The 4S trial with simvastatin in a younger population (average age 59) found a 30% reduction in total mortality (RR 0.70, 95% CI 0.58-0.85) [1]. The LIPID trial with pravastatin found a 22% reduction in total mortality (RR 0.78, 95% CI 0.69-0.87) [1]. These are the landmark secondary prevention trials, and they show genuine benefit.

For primary prevention in a 69-year-old, the picture is much weaker. The CTT meta-analysis, which pooled 28 trials and 147,242 participants, found that in people aged 75 or older with no known vascular disease, statin therapy reduced major vascular events by only 8%, and that result did not reach statistical significance (95% CI 0.73-1.16) [13]. The PROSPER trial's primary prevention subgroup (people without known vascular disease) showed a hazard ratio of 0.94 (95% CI 0.77-1.15), meaning no statistically significant benefit [13]. A 2005 retrospective cohort study of 1,056 patients found that in those aged 65 or older, statin adherence was not associated with a significant reduction in the composite cardiovascular endpoint (adjusted HR 0.87, 95% CI 0.61-1.26) or in myocardial infarction (adjusted HR 0.77, 95% CI 0.17-3.40) [3]. The benefit seen in younger patients (under 65, HR 0.14 for MI) simply did not replicate in older patients [3].

The harms are real. Statins increase the risk of new-onset diabetes by 9-13% in meta-analyses, and higher doses increase that risk further [25]. Myopathy, though rare at standard doses (excess incidence about 0.06% over 5 years with simvastatin 40 mg), becomes more common at higher doses: atorvastatin 80 mg carried a 0.53% myopathy rate compared to 0.08% at 40 mg [26, 28]. Liver enzyme elevations occur in about 0.2% of patients on simvastatin, though most are transient and not clinically significant [26]. The risk of hemorrhagic stroke may be increased: the SPARCL trial with atorvastatin 80 mg found a hazard ratio of 1.66 (95% CI 1.08-2.55) for hemorrhagic stroke [15]. A meta-analysis of 38 trials found a non-significant trend toward more hemorrhagic strokes with statins (RR 1.16, 95% CI 0.75-1.80) [5].

The 2019 ESC/EAS guidelines would classify about 90% of people aged 70-75 as eligible for statins for primary prevention [35]. That is a policy choice, not a reflection of strong evidence. The modeling behind that guideline estimates that treating everyone aged 40-75 for 10 years would prevent about 25% of ASCVD events, with a number needed to treat of 19 [35]. But that assumes full adherence and a 25% risk reduction per mmol/L of LDL lowering, which is an extrapolation from secondary prevention trials, not a finding from primary prevention trials in older adults.

My call: if this 69-year-old man has already had a heart attack or stroke, a moderate-dose statin is reasonable, with the understanding that the benefit is real but modest and the side effects are real too. If he has never had a cardiovascular event, the evidence does not support starting a statin. The benefit is too small to justify the diabetes risk, muscle symptoms, and the burden of daily medication. The burden of proof is on the intervention, and for primary prevention in a 69-year-old, that burden has not been met.

Confidence: moderate for secondary prevention, high for the conclusion that primary prevention lacks adequate evidence in this age group.